The role of advanced diagnostics on precision medicine in hemato oncology

Abstract

Advanced diagnostic technologies are driving precision medicine to revolutionize the field of hemato-oncology, that enable personalized treatments based on detailed molecular and genetic profiles. Innovations like next-generation sequencing, digital PCR, and liquid biopsies have reshaped diagnosis, classification, and treatment decisions in hematologic cancers such as leukemia, lymphoma, and myeloma. Each technology offers unique strengths NGS provides broad mutational insights, digital PCR enables ultra-sensitive measurable residual disease detection, and flow cytometry delivers rapid, accessible analysis while also facing specific limitations. This review explores how these tools collectively improve early detection, prognostication, and tailored therapy, enhancing patient outcomes. However, challenges persist, including tumor clonal diversity, microenvironmental influences, and unequal access due to cost and regulatory barriers. Future progress hinges on integrating multi-omics data, enhancing diagnostic accuracy, and expanding accessibility to fully harness personalized hemato-oncology, paving the way for more effective, individualized treatments and improved survival.

Introduction

Precision medicine has transformed the field of hemato-oncology by tailoring medical treatment to individual patients' specific genetic, molecular, and clinical characteristics. Hematological malignancies, which include leukemia, lymphoma, and myeloma, are among the most genetically and molecularly diverse cancers, posing significant diagnostic, risk assessment, and treatment challenges [1] Traditional diagnostic methods, such as morphological analysis, cytogenetics, and immunophenotyping, have provided valuable insights into disease classification, but often fall short in capturing the full range of genetic and molecular abnormalities driving these cancers as a result, treatment approaches have frequently been generalized, leading to less-than-optimal outcomes for many patients [2, 3]. The discovery of the BCR: ABL1 fusion gene in chronic myeloid leukemia (CML) ushered in the era of precision medicine in hemato-oncology. This discovery not only clarified the molecular basis of CML but also led to the development of imatinib, a tyrosine kinase inhibitor that revolutionized treatment by targeting this specific genetic abnormality [4, 5]. The success of imatinib demonstrated the transformative power of precision medicine in improving outcomes for patients with hematological malignancies. Since then, targeted therapies have been developed for other hematological cancers, such as FLT3 inhibitors like gilteritinib for FLT3 mutations, which have significantly improved patient outcomes by targeting specific molecular pathways [6]. Traditional diagnostic methods, such as morphological analysis, cytogenetics, and immunophenotyping, have provided valuable insights into disease classification, but often fall short in capturing the full range of genetic and molecular abnormalities driving these cancers. As a result, treatment approaches have frequently been generalized, leading to less-than-optimal outcomes for many patients [7]. In recent years, advances in high-throughput technologies and molecular diagnostics have transformed our understanding and management of hematological malignancies. Precision medicine uses tools such as next-generation sequencing (NGS), liquid, and functional assays to identify actionable molecular targets with unparalleled precision [7, 8]. These advancements allow clinicians to classify diseases more accurately, predict prognoses more reliably, and choose therapies tailored to each patient's genetic and molecular profile. For example, genomic profiling has revealed key mutations such as FLT3 in acute myeloid leukemia (AML) and TP53 in chronic lymphocytic leukemia (CLL), which guide prognosis and therapeutic decisions [9].

The discovery of the BCR: ABL1 fusion gene in chronic myeloid leukemia (CML) ushered in the era of precision medicine in hemato-oncology. This discovery not only clarified the molecular basis of CML but also led to the development of imatinib. This tyrosine kinase inhibitor revolutionized treatment by targeting this specific genetic abnormality [10]. The success of imatinib demonstrated the transformative power of precision medicine in improving outcomes for patients with hematological malignancies. Since then, targeted therapies have been developed for other hematological cancers, such as FLT3 inhibitors like gilteritinib for FLT3 mutations, which have significantly improved patient outcomes by targeting specific molecular pathways [11].

Advanced diagnostic technologies are at the heart of precision medicine, providing a more in-depth understanding of disease biology. High-throughput sequencing methods, such as NGS, enable comprehensive analysis of multiple genes at the same time, identifying mutations that drive disease progression or confer resistance to [12]. This can be shown as, mutations in IDH1/IDH2 or NPM1 in AML guide treatment choices, while markers like IGHV mutation status or TP53 mutations in CLL inform therapeutic strategies [13]. Liquid biopsies, which examine circulating tumor DNA (ctDNA) or circulating tumor cells, are a non-invasive method of monitoring disease progression and tracking measurable residual disease after treatment, providing critical information for detecting early signs of relapse. Furthermore, functional precision medicine is emerging, combining ex vivo drug sensitivity testing with genomic data to find effective therapies for patients with refractory or relapsed diseases [14–16].

However, implementing precision medicine in hemato-oncology poses several challenges. Clonal heterogeneity, a hallmark of hematological malignancies, complicates treatment strategies because cancer cells evolve over time [17]. The tumor microenvironment, which affects drug sensitivity and resistance, is still poorly understood [18]. Moreover, the high cost of advanced diagnostics and targeted therapies raises concerns about equitable access, particularly in resource-limited settings, while therapies have been developed for common genetic drivers, treatment options for rare mutations or less-studied subtypes remain limited [19–21].

In recent years, advances in high-throughput technologies and molecular diagnostics have transformed our understanding and management of hematological malignancies [21–24]. In the future, precision medicine in hemato-oncology will require the integration of multi-omics data combining genomic, transcriptomic, proteomic, and metabolomic analyses to provide a comprehensive view of each patient's disease [25]. AI and machine learning algorithms will play an important role in analyzing complex datasets to identify novel biomarkers and optimize treatment pathways [26]. In conclusion, advanced diagnostics have significantly altered the landscape of hemato-oncology, allowing precision medicine approaches that tailor treatments to individual patients' molecular profiles. Despite significant progress in the development of targeted therapies and functional precision medicine, challenges such as clonal complexity, cost barriers, and limited treatments for rare mutations persist. Continuous research into innovative diagnostic tools and therapeutic strategies will be critical in unlocking the full potential of precision medicine in improving outcomes for patients with hematological malignancies [27–29].

Mechanisms

The integration of advanced diagnostics into hemato-oncology has fundamentally transformed the way hematological malignancies are classified, monitored, and treated. However, it is crucial to recognize that each diagnostic platform has unique mechanisms, strengths, and limitations. One of the key mechanisms driving this revolution is enhanced disease classification Traditional diagnostic methods, such as morphological analysis and cytogenetics, frequently underestimate the complexity of hematological cancers. Advanced tools such as next-generation sequencing (NGS), immunophenotyping, and fluorescence in situ hybridization (FISH) provide detailed molecular and genetic profiles for these diseases, allowing for more precise and nuanced classification. This allows clinicians to identify specific genetic mutations and disease subtypes, significantly improving the precision of treatment plans, ensuring that therapies are tailored to the unique genetic makeup of the patient's cancer. As a result, treatments are more effective and targeted, reducing the likelihood of unnecessary side effects and improving patient outcomes. NGS offers unparalleled breadth in detecting known and novel mutations across multiple genes, making it ideal for comprehensive disease characterization and identifying actionable targets. However, NGS can be limited by lower sensitivity for detecting rare residual clones and may require complex bioinformatics support [30–32].

Another way advanced diagnostics are revolutionizing hemato-oncology is through improved risk stratification and prognosis. Identifying key genetic mutations, such as FLT3 in acute myeloid leukemia (AML) or TP53 in chronic lymphocytic leukemia (CLL), allows clinicians to better predict disease progression and how specific treatments will work. This increased understanding of the genetic landscape enables risk-adapted treatment strategies, in which therapies are tailored not only to the type of cancer, but also to the individual's likelihood of progression and response to treatment. Precision medicine ensures that patients receive the right level of therapy by minimizing unnecessary aggressive treatments for low-risk patients and intensifying therapies for those at higher risk [33–35].

The ability to select targeted therapies is another transformative feature made possible by advanced diagnostics. NGS, qPCR, and immunophenotyping technologies enable clinicians to identify actionable molecular targets such as BCR: ABL1 in chronic myeloid leukemia (CML) and IDH1/IDH2 mutations in AML. By identifying the specific drivers of the disease, clinicians can choose therapies that directly target these abnormalities, such as tyrosine kinase inhibitors or FLT3 inhibitors. These therapies specifically inhibit the molecular mechanisms driving cancer, thus improving therapeutic efficacy while minimizing off-target effects and side effects that frequently accompany traditional, broad-spectrum chemotherapy [20, 36–38].

Furthermore, non-invasive monitoring of disease progression using techniques such as liquid biopsies is changing the way hematological cancers are tracked and managed. Liquid biopsies detect circulating tumor DNA (ctDNA) in blood samples, providing a non-invasive, real-time snapshot of the tumor's genetic landscape. This enables clinicians to monitor tumor dynamics without the need for multiple invasive biopsies. The ability to early detect disease progression and predict relapse risk offers a critical advantage in quickly adjusting treatment strategies, ensuring that interventions can be made before a patient's condition worsens, thus improving long-term outcomes. However, ctDNA analysis may be limited by low abundance of tumor DNA in some patients and requires highly sensitive assays to avoid false negatives [39–41]. Advanced diagnostics also make it possible to detect Minimal Residual Disease (MRD). Using ultra-sensitive techniques such as NGS or quantitative PCR (qPCR), clinicians can detect even the smallest amounts of cancer cells that survive treatment. NGS offers unparalleled breadth in detecting known and novel mutations, while qPCR-based diagnostics remain essential for targeted, rapid, and affordable mutation detection [42–44]. This is especially important for predicting relapse because the presence of MRD frequently indicates the likelihood of recurrence. Flow cytometry is rapid, widely available, and effective for immunophenotypic MRD detection, but its sensitivity (typically 10^-4) is lower than that of molecular methods (up to 10^-6), Flow cytometry and immunophenotyping are widely used for MRD tracking, offering rapid and sensitive detection of residual disease [45, 46]. Its monitoring enables clinicians to make informed decisions about additional therapeutic interventions, such as stem cell transplants or maintenance therapy, significantly improving survival rates and lowering the risk of relapse. Digital PCR, provides ultra-sensitive quantification of specific mutations or fusion transcripts, making it the gold standard for MRD monitoring when the target is known. Yet, its narrow focus limits its use in initial diagnosis or in diseases with high genetic heterogeneity [47–49].

The use of artificial intelligence and machine learning is increasingly important for integrating complex diagnostic data and optimizing treatment decisions [50, 51]. AI algorithms can analyze complex datasets, detecting subtle genetic and clinical patterns that human clinician may miss. These algorithms help to optimize treatment strategies by improving the ability to predict disease behavior, assess therapeutic responses, and tailor care plans to the individual's unique genetic profile, ensuring that each patient receives the most effective and personalized care. AI tools can integrate data from multiple diagnostic modalities, but their clinical utility depends on robust validation and regulatory approval [52–54].

Finally, Multi-omics approaches, including proteomics, provide a more comprehensive understanding of tumor biology and may reveal novel biomarkers for early detection and treatment stratification [55]. the integration of multi-omics approaches, which include genomics, proteomics, and metabolomics, provides a comprehensive understanding of tumor biology. Researchers and clinicians can identify novel biomarkers for early detection and treatment stratification by examining the tumor at multiple levels, including genetic, protein, and metabolic. This comprehensive understanding enables the development of more refined, personalized therapeutic strategies, furthering the field of hemato-oncology and improving patient outcomes [56–58].

In conclusion, advanced diagnostics are transforming hemato-oncology by enabling precision medicine via detailed molecular insights. while advanced diagnostics have transformed hemato-oncology, clinicians must carefully select the appropriate technology based on clinical context, disease type, and available resources. These technologies not only improve disease classification, risk stratification, and targeted therapy selection, but they also enable non-invasive monitoring, the application of AI and multi-omics approaches. Collectively, these innovations are transforming the landscape of hematological cancer treatment, offering more personalized, effective, and efficient care to patients [59–61].

Methods

This review was conducted rigorously using the PRISMA framework to aid transparency and reproducibility. It also included an extensive literature review available on popular databases like PubMed, Scopus, and Web of Science for peer-reviewed articles, market reports, and industry publications dated January 2010 to May 2025. The search strategy focused on, “hemato-oncology diagnostics,” “precision medicine,” “next generation sequencing,” “liquid biopsy,” “measurable residual disease (MRD) monitoring,” and “oncology specific artificial intelligence” along with other terms related to blood cancers like “leukemia,” “lymphoma,” and “myeloma.”

Inclusion criteria included all studies describing the diagnostic methods and technologies used in relation to hematologic cancers, including clinical studies, meta-analyses, guidelines, and relevant parts of market analysis. Studies that were non-diagnostic in nature such as purely therapeutic or preclinical animal research, editorials, abstracts of conferences, and non-peer reviewed documents were excluded. The first search yielded more records which was later reduced after removing duplicates. Titles and abstracts went through relevance screening followed by a full text review of articles which led to some relevant studies that underwent inclusion criteria.

Current diagnostic approaches in hemato-oncology

Molecular diagnostics have transformed the field of hemato-oncology by providing more precise and effective methods for diagnosing and monitoring hematological malignancies. However, the choice of technology should be guided by the clinical question broad profiling (NGS), MRD tracking (digital PCR or flow cytometry), or non-invasive monitoring (liquid biopsy. Next-generation sequencing (NGS) is a fundamental technology that allows for comprehensive genomic profiling to identify key mutations such as FLT3 in acute myeloid leukemia (AML) and BCR-ABL1 in chronic myeloid leukemia (CML). NGS’s main advantage is its ability to detect a wide range of genetic variants in a single assay, but it is less sensitive than digital PCR for detecting low-level MRD and is more expensive. NGS enables the detection of a wide range of genetic variants, allowing clinicians to better understand the underlying molecular drivers of disease and tailor treatment strategies accordingly. Another important molecular tool is quantitative PCR (qPCR), which is commonly used to monitor measurable residual disease (MRD) in cancers such as acute lymphoblastic leukemia (ALL) and AML. Digital PCR improves upon qPCR by offering higher sensitivity and absolute quantification, but both are limited to known targets [62–64].

Liquid biopsies, which analyze circulating tumor DNA (ctDNA) or RNA from blood samples, provide a minimally invasive method for tracking tumor dynamics in real -time. This technique is gaining popularity in hemato-oncology because it can provide actionable insights without the need for traditional tissue biopsies. As an illustration, ctDNA analysis has demonstrated promise in predicting relapse risk in young adults with ALL, making it a valuable tool for managing long-term treatment strategies. While promising, liquid biopsies require further validation for routine use, as ctDNA levels can be low or undetectable in some patients [65–67].

Immunophenotyping, primarily via flow cytometry, remains an effective diagnostic tool in hemato-oncology. By analyzing cell surface markers, this technique aids in the classification of hematological cancers such as lymphomas and leukemias, providing critical information for treatment selection and outcome. Furthermore, cytogenetic techniques, including fluorescence in situ hybridization (FISH), are essential for detecting chromosomal abnormalities which is emerged as a critical prognostic tool, helping to predict relapse and inform decisions on future therapeutic interventions. translocations in CML, which aids in diagnosis and risk stratification [68, 69].

One of the most significant advances in hemato-oncology is Measurable Residual Disease (MRD) monitoring, which employs ultra-sensitive techniques such as NGS or digital PCR to detect minimal cancer presence after treatment. MRD monitoring has emerged as a critical prognostic tool, helping to predict relapse and inform decisions on future therapeutic interventions [8, 70] (Table 1).

Table 1.

Comparative Summary of Diagnostic Techniques for Hematologic Malignancies

Diagnostic Modality	Principle/Technology	Sensitivity	Strengths	Limitations	Clinical applications
Morphology & histopathology	Microscopic examination	Moderate	Rapid initial diagnosis	Limited molecular info	Initial diagnosis, classification
Flow cytometry	Immunophenotyping of cell markers	10^-4 to 10^-5 (MRD)	Rapid, multiparametric, MRD detection	Requires fresh samples, operator-dependent	Diagnosis, MRD monitoring
Cytogenetics & FISH	Chromosome analysis, probes	Moderate	Detects structural abnormalities	Time-consuming, lower resolution	Prognosis, classification
qPCR	Targeted mutation quantification	10^-5	High sensitivity, cost-effective	Limited to known mutations	MRD detection, mutation tracking
Digital PCR	Partitioned PCR for quantitation	10^-6	Ultra-sensitive, precise quantification	Limited multiplexing	MRD, minimal clone detection
Next-generation sequencing (NGS)	Massive parallel sequencing	10^-4 to 10^-6	Broad mutation profiling, discovery	High cost, data complexity	Comprehensive genomic profiling, MRD
Liquid biopsy	ctDNA/CTC analysis	Variable (10^-3 to 10^-6)	Minimally invasive, dynamic monitoring	Sensitivity varies, standardization lacking	Disease monitoring, relapse detection

Diagnostic workflow and clinical applications in hemato-oncology

Initial diagnosis → NGS for broad profiling → MRD assessment by digital PCR/flow cytometry → Longitudinal monitoring by liquid biopsy.

Emerging trends in hemato-oncology diagnostics

Several new trends are changing the landscape of diagnostic approaches in hemato-oncology. One of the most promising advancements is the incorporation of AI into diagnostics. Machine learning algorithms are increasingly being used to analyze large datasets and improve diagnostic accuracy, especially in leukemia. AI can help identify subtle patterns in genetic and clinical data that are not immediately apparent, resulting in more precise treatment strategies [71–73].

Multi-omics approaches, which combine genomics, proteomics, and metabolomics, offer a comprehensive understanding of tumor biology. By combining these various layers of biological data, researchers and clinicians can discover new biomarkers for early detection, treatment stratification, and the development of personalized therapeutic strategies. Furthermore, advances in liquid biopsies are expanding their utility, with improved sensitivity in ctDNA assays, enhancing the potential for early diagnosis and monitoring of rare mutations that may not be detectable through conventional methods [74, 75].

Another significant trend is the advancement of point-of-care testing, in which portable diagnostic devices are designed to provide quick results at the bedside or in outpatient settings. This innovation is particularly valuable in resource-limited environments, offering better access to diagnostic tools and reducing the time required for critical decision-making [76, 77].

Finally, drug-diagnostic collaboration is hastening the implementation of precision medicine in hemato-oncology. By developing companion diagnostics alongside targeted therapies, the healthcare industry enables more personalized and effective treatments for patients with hematological cancers, ensuring that the right drug is matched with the right patient at the right time [78, 79].

Lastly, significant advances in molecular diagnostics, such as NGS, qPCR, and liquid biopsies, have improved our ability to accurately monitor, diagnose, and treat hematological malignancies. Emerging technologies such as AI, multi-omics, and point-of-care testing are further propelling the field forward, offering the potential to revolutionize cancer care by providing more person.

Challenges and limitations in implementing advanced diagnostics in hemato-oncology

While advanced diagnostics have significantly advanced the field of hemato-oncology, a number of challenges remain that prevent widespread implementation and accessibility.

Cost and accessibility

High costs remain one of the most significant barriers, especially for advanced technologies like next-generation sequencing (NGS). While NGS provides unparalleled insight into the genetic and molecular drivers of hematological malignancies, its high cost restricts its availability, especially in low-income or resource-constrained areas. Due to the disparity in access to cutting-edge diagnostic tools, many patients in underserved areas continue to rely on traditional methods that may not provide the same level of accuracy or predictive power [80–82]. High costs remain a primary barrier, particularly for resource-intensive technologies like NGS, which, while providing comprehensive genomic insights, are often prohibitively expensive for many healthcare systems, especially in low- and middle-income countries. This economic disparity results in limited availability of advanced diagnostics in underserved regions, where patients frequently rely on less sensitive traditional methods such as cytogenetics or flow cytometry, which may not capture the full molecular complexity of hematologic malignancies[61, 83, 84]. Efforts to develop cost-effective alternatives, including targeted gene panels and streamlined sequencing protocols, show promise but require further validation and standardization before widespread clinical implementation [85, 86].

Regulatory and standardization challenges

In addition to the cost, regulatory complexities pose a significant challenge to the integration of novel diagnostic tools into global healthcare systems. The lack of standardization in regulatory frameworks across countries and healthcare settings makes universal adoption of new technologies difficult. Variations in approval processes, quality control measures, and reimbursement policies can slow the adoption of promising diagnostic innovations, preventing patients from receiving the most advanced care possible. As a result, despite the promise of precision medicine, there is still a gap between technologies developed in research labs and their practical use in clinical settings [87, 88]. It impedes the integration of novel diagnostics into routine care. The lack of harmonized global regulatory frameworks leads to variable approval processes, quality control standards, and reimbursement policies, which slow the adoption of innovative technologies [85]. Additionally, the absence of standardized protocols for sample handling, data analysis, and reporting contributes to inconsistencies in diagnostic accuracy and clinical interpretation, complicating the translation of genomic data into actionable treatment decision [89]. Addressing these gaps requires coordinated international efforts to establish universal guidelines and quality assurance measures.

Biological complexity and clonal evolution

Another significant barrier is clonal evolution, which complicates the diagnosis and monitoring of hematological cancers. Hematological malignancies are characterized by a high degree of genetic heterogeneity, with cancer cells changing significantly over time. This clonal evolution can cause different subclones of the tumor to appear at different stages of the disease, making it difficult to accurately track disease progression or predict how it will respond to treatment. This phenomenon can result in situations in which a patient initially responds well to treatment, only to relapse due to the emergence of resistant cancer clones. Such complexity necessitates highly sophisticated diagnostic tools and ongoing monitoring, compounding the difficulties faced by both clinicians and patients in managing these diseases [90, 91]. The dynamic nature of hematologic malignancies, characterized by extensive genetic heterogeneity and clonal evolution, presents a formidable challenge for diagnostics. This clonal diversity often leads to treatment resistance and relapse, which may not be detected by standard assays due to sensitivity limitations. Consequently, longitudinal and highly sensitive multi-modal diagnostic approaches are necessary but increase the complexity and cost of patient management [86, 92, 93].

Practical implementation and interpretation challenges

Implementing advanced diagnostic tools in clinical practice demands specialized infrastructure, trained personnel, and sophisticated bioinformatics capabilities. The interpretation of complex molecular and multi-omics data requires expertise that may not be universally available, leading to variability in diagnostic conclusions and clinical decisions [94, 95]. Furthermore, the integration of diverse data types from cytogenetics to sequencing and proteomics into coherent clinical reports remains a challenge, as current workflows and information systems are often fragmented [89, 96]. Emerging solutions leveraging artificial intelligence and machine learning aim to improve data integration and interpretation but are still under development [97–100].

Conclusion

Hemato-oncology has made substantial progress with the adoption of advanced diagnostic technologies, which provide comprehensive insights into the genetic and molecular heterogeneity of hematologic malignancies. These tools such as next-generation sequencing (NGS), liquid biopsies, and measurable residual disease (MRD) assessment via digital PCR and flow cytometry enable more individualized and focused treatment plans that have the potential to improve patient outcomes. For instance, liquid biopsies offer a minimally invasive means for disease monitoring, NGS delivers broad genomic profiling, and MRD assessment allows for sensitive detection of residual disease. However, each technology presents distinct advantages and limitations: NGS excels at detecting a wide range of mutations but can be costly and time-consuming; liquid biopsies facilitate dynamic tumor monitoring but may lack the sensitivity to detect low-frequency subclones; and MRD monitoring methods vary in sensitivity and applicability depending on the clinical context.

Despite these advances, several challenges remain in translating these technologies into routine clinical practice. High costs and complex regulatory pathways can limit accessibility, particularly in resource-constrained settings. Additionally, tumor clonal evolution complicates disease monitoring, as emerging subpopulations may evade detection with current assays. These limitations highlight the need for ongoing technological refinement, standardization of diagnostic approaches, and initiatives to improve equitable access.

Looking ahead, the integration of artificial intelligence-driven data analysis and multi-modal diagnostics holds promise for enhancing diagnostic accuracy and clinical utility. By critically evaluating and combining these complementary technologies, hemato-oncology can move beyond descriptive diagnostics toward truly personalized and adaptive treatment strategies. Continued research and innovation will be essential to address existing limitations and ensure that advances in precision medicine translate into improved survival and quality of life for all patients.

Recommendations

Hemato-oncology has made remarkable strides through advanced diagnostic technologies such as next-generation sequencing (NGS), liquid biopsies, and measurable residual disease (MRD) monitoring, which have been pivotal in realizing the promise of precision medicine. Yet, significant barriers remain that limit their widespread clinical impact. Foremost among these is the high cost and limited accessibility of these tools, particularly in low-resource settings. To democratize precision oncology, concerted efforts must focus on reducing costs, streamlining workflows, and expanding global access to ensure equitable patient benefit.

Moreover, the inherent complexity of hematologic malignancies driven by clonal evolution and tumor heterogeneity poses ongoing challenges for accurate disease monitoring and effective treatment. Addressing this requires the development of ultra-sensitive, dynamic diagnostic methods capable of detecting emerging resistant clones and subtle genetic alterations before clinical relapse. Integrating multi-omics data with artificial intelligence and machine learning holds great promise for unraveling tumor biology, improving prognostic accuracy, and guiding adaptive therapeutic strategies.

In addition, expanding research to include rare mutations and understudied disease subtypes is critical to broadening the therapeutic landscape and delivering truly personalized care to all patient populations. Liquid biopsies, as minimally invasive tools, offer unique advantages for real-time disease surveillance and early relapse detection, which could translate into improved long-term outcomes.

Ultimately, overcoming these challenges demands stronger collaboration among researchers, clinicians, industry stakeholders, and policymakers to foster innovation, standardize diagnostic practices, and implement equitable healthcare solutions. By embracing these priorities, the field can accelerate the transition from descriptive diagnostics to predictive, personalized, and accessible care transforming outcomes for patients with hematologic cancers worldwide.

Abbreviations

NGS

Next-generation sequencing

MRD

Measurable residual disease

AML

Acute myeloid leukemia

CLL

Chronic lymphocytic leukemia

CML

Chronic myeloid leukemia

QPCR

Quantitative PCR (polymerase chain reaction)

ALL

Acute lymphoblastic leukemia

CTDNA

Circulating tumor DNA

FISH

Fluorescence in situ hybridization

AI

Artificial intelligence

DLBCL

Diffuse large B-cell lymphoma

Author contributions

BM: Coordinated the review process and contributed to the manuscript’s revision. AM: Provided critical insights and revisions to the manuscript content. AK: Contributed to the review of the manuscript and provided valuable suggestions for improving the content. D M: Conceptualization, methodology, data collection, formal analysis, and writing original draft preparation. B B: Data curation, investigation, and writing review and editing. YM: Software, validation, and visualization. Z M: Resources, project administration, and supervision. T A: supervision, and manuscript review.

Funding

The authors declare that they did not receive any funding for this work.

Availability of data and materials

No datasets were generated or analysed during the current study.

Declarations

Ethical approval and consent to participate

This review solely utilized scientific background information and findings from other research studies. No patient data was used, and there was no direct participant involvement. All information was carefully reviewed to ensure adherence to ethical guidelines and standards.

Consent for publication

Not applicable. This manuscript does not contain any individual persons’ data.

Competing interests

The authors declare no competing interests.